Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer

10 Aug 2021

Abstract excerpt

Abstract Purpose: FGFR2 amplification is associated with poor prognosis in advanced gastric cancer and its subclonal heterogeneity has been revealed. Here, we examined whether circulating tumor DNA (ctDNA) was useful for detecting FGFR2 amplification and co-occurring resistance mechanisms in advanced gastric cancer. Experimental Design: We assessed genomic characteristics of FGFR2-amplified advanced gastric...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Gastrointestinal Tumor Research and Treatment
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34376535
DOI: 10.1158/1078-0432.ccr-21-1414

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric CancerPMID 34376535Read ↗

Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.Semantic proximity Read ↗

Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers.Semantic proximity Read ↗

Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancerSemantic proximity Read ↗

Real-world genomic landscape of FGFR2 amplifications and fusions in solid tumors: analysis of 4,953 patients using clinical-grade NGSSemantic proximity Read ↗

Molecular evolutionary process of advanced gastric cancer during sequential chemotherapy detected by circulating tumor DNA.Semantic proximity Read ↗

Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and OncogenesisSemantic proximity Read ↗

Circulating Tumor DNA Sequencing Analysis of Gastroesophageal AdenocarcinomaSemantic proximity Read ↗

FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival.Semantic proximity Read ↗

Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancerSemantic proximity Read ↗

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.Semantic proximity Read ↗

Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2‐targeted therapiesSemantic proximity Read ↗

FGFR2 gene amplification and clinicopathological features in gastric cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.